T-DM1 + Pertuzumab: Combination therapy involving the ADC T-DM1 and the HER2 inhibitor pertuzumab has been explored in several phase 3 clinical trials for the treatment of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.